Cassava Sciences Inc represents values of innovation, integrity, and dedication to improving the lives of patients. The company's corporate philosophy revolves around developing and commercializing therapies for Alzheimer's disease, with a strong focus on scientific rigor and patient-centric approaches. Cassava Sciences Inc is committed to conducting clinical studies, advancing research, and collaborating with experts in the field to address the urgent need for effective Alzheimer's treatments. With its cutting-edge scientific expertise and passion for making a difference, Cassava Sciences Inc strives to be a leader in the biopharmaceutical industry.

Cassava Sciences Inc is primarily present in the United States of America.

Cassava Sciences Inc, a leading biopharmaceutical company, has successfully achieved several significant milestones. One notable accomplishment is the development of PTI-125, a novel drug candidate for the treatment of Alzheimer's disease. Cassava Sciences Inc has also undertaken successful clinical trials, demonstrating promising results in improving cognitive function and reducing disease-related biomarkers in patients with Alzheimer's. Additionally, the company secured FDA's Fast Track designation for PTI-125, highlighting its potential as a breakthrough therapy. Cassava Sciences Inc's dedication to advancing innovative treatments for neurodegenerative diseases has positioned them as a front-runner in the pharmaceutical industry.

Cassava Sciences Inc, founded in 1998, is a biopharmaceutical company focused on the development of innovative drugs for the treatment of Alzheimer's disease. The company's mission is to provide hope to patients and their families by advancing scientific research and clinical trials. Cassava Sciences Inc has dedicated years of research to elucidate the underlying causes of Alzheimer's disease and develop an effective treatment approach. With a strong emphasis on innovation and collaboration, the company has made significant strides in advancing their drug candidate, PTI-125, through clinical trials. Cassava Sciences Inc's commitment to addressing this critical unmet medical need has positioned the company as a leader in the Alzheimer's research field.

Some of the main competitors of Cassava Sciences Inc in the market include Biogen Inc, Eli Lilly and Company, and Roche Holding AG.

Cassava Sciences Inc is primarily active in the pharmaceutical and biotechnology industries.

The business model of Cassava Sciences Inc revolves around the development of innovative drugs to address neurodegenerative diseases, with a particular focus on Alzheimer's disease. The company utilizes its proprietary technology and scientific expertise to identify and develop small molecule drug candidates that target the abnormal accumulation of tau proteins in the brain, a hallmark feature of Alzheimer's disease. Through rigorous research and clinical trials, Cassava Sciences aims to bring safe and effective treatments to patients, ultimately improving their quality of life.

Cassava Sciences KGV ir -12,95.

Cassava Sciences KUV ir 0.

AlleAktien kvalitātes vērtējums Cassava Sciences ir 2/10.

Pašreiz nevar aprēķināt apgrozījumu Cassava Sciences.

gaidāmā Cassava Sciences peļņa ir -38,17 milj. USD.

Cassava Sciences Inc is a biopharmaceutical company focused on the development of therapies for neurodegenerative diseases. The company is working on the development of drugs for the treatment of Alzheimer's disease, which is one of the most common neurodegenerative diseases. The company's business model is based on the development of novel drugs to improve the memory and cognitive function of patients with Alzheimer's disease. Cassava Sciences Inc has a comprehensive understanding of the pathophysiology of the disease and is working on the identification of compounds that can slow down the progression of the disease. One of the company's key products is the drug candidate PTI-125, which is currently being tested in phase 2 studies. PTI-125 is a peptide molecule that reduces amyloid breakdown and neuroinflammation in the brain. The use of PTI-125 is expected to contribute to the improvement of cognitive function in patients with Alzheimer's. Cassava Sciences Inc also has a pipeline of drug candidates, including PTI-125, PTI-125D, and PTI-333. These drug candidates target various aspects of Alzheimer's disease, including amyloid reduction, tau reduction, and inflammation inhibition. The company also uses a licensing model to fund its research and development. In 2018, the Japanese company Takeda acquired an exclusive license to develop and market PTI-125 in Japan. Cassava Sciences Inc received an upfront payment of $30 million, as well as future milestone payments and licensing fees. Additionally, Cassava Sciences Inc has a comprehensive intellectual property portfolio in the field of Alzheimer's therapy. The company has filed 16 patents and owns 7 granted patents in the US and Europe. Cassava Sciences Inc collaborates with leading academic institutions and research facilities to accelerate the research and development of its drug candidates. The company also has its own clinical department to evaluate its drug candidates in clinical trials. In summary, Cassava Sciences Inc's business model is focused on developing novel therapies to improve the memory and cognitive function of patients with Alzheimer's disease. The company has a strong pipeline of drug candidates and uses a licensing model to fund its research and development. Collaboration with leading academic institutions and research facilities, as well as protection of intellectual property, are important elements of Cassava Sciences Inc's business model.

Cassava Sciences izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Cassava Sciences vai uzņēmums nedod dividendes.

Cassava Sciences ISIN ir US14817C1071.

Cassava Sciences WKN ir A2PGL8.

Cassava Sciences simbols ir SAVA.

Pēdējo 12 mēnešu laikā Cassava Sciences maksāja dividendes 5,25 USD apmērā. Tas atbilst aptuveni 44,53 % dividendes ražībai. Nākamajos 12 mēnešos Cassava Sciences plāno maksāt dividendes 0 USD apmērā.

Cassava Sciences pašreizējā dividendu rentabilitāte ir 44,53 %.

Cassava Sciences maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Cassava Sciences pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Cassava Sciences tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Cassava Sciences apmērā 0,75 USD, kas tika izmaksāta 24.12.2012., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 13.12.2012..

Pēdējās dividendes izmaksa notika 24.12.2012..

Gadā 2023, Cassava Sciences izmaksāja 0 USD dividendes.

Cassava Sciences dividendes tiek izmaksātas USD.